サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：放射線皮膚炎市場のシェア・規模・動向・産業分析・予測 (2023年～2032年)： 製品 (局所剤・経口剤・ドレッシング材)・流通チャネル・地域別
市場調査レポート
商品コード
1219509

放射線皮膚炎市場のシェア・規模・動向・産業分析・予測 (2023年～2032年)： 製品 (局所剤・経口剤・ドレッシング材)・流通チャネル・地域別

Global Radiodermatitis Market Share, Size, Trends, Industry Analysis Report, By Product (Topical, Oral, and Dressings); By Distribution Channel; By Region; Segment Forecast, 2023 - 2032
出版日: | 発行: Polaris Market Research | ページ情報: 英文 118 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
放射線皮膚炎市場のシェア・規模・動向・産業分析・予測 (2023年～2032年)： 製品 (局所剤・経口剤・ドレッシング材)・流通チャネル・地域別
出版日: 2023年01月01日
発行: Polaris Market Research
ページ情報: 英文 118 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の放射線皮膚炎の市場規模は、2032年には6億4,958万米ドルの規模に成長すると予測されています。

当レポートでは、世界の放射線皮膚炎の市場を調査し、市場概要、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界の放射線皮膚炎市場の洞察

  • 放射線皮膚炎：産業のスナップショット
  • 放射線皮膚炎：市場力学
    • 成長推進因子・機会
    • 成長抑制因子・課題
  • ポーターのファイブフォース分析
  • PESTLE分析
  • 放射線皮膚炎産業の動向
  • バリューチェーン分析
  • COVID-19：影響分析

第5章 世界の放射線皮膚炎市場：製品別

  • 主な調査結果
  • 局所剤
    • コルチコステロイド
    • 親水性クリーム
    • 抗生物質
    • その他
  • 経口剤
  • ドレッシング材
    • ハイドロゲル&ハイドロコロイドドレッシング材
    • 非刺激性バリアフィルム
    • 蜂蜜含浸ガーゼ
    • シリコーン被覆ドレッシング材
    • その他

第6章 世界の放射線皮膚炎市場：流通チャネル別

  • 主な調査結果
  • 病院薬局
  • 小売薬局
  • オンライン

第7章 世界の放射線皮膚炎市場：地域別

  • 主な調査結果
  • 北米
  • 欧州
  • アジア太平洋
  • 中東およびアフリカ
  • ラテンアメリカ

第8章 競合情勢

  • 拡張・買収の分析
  • 提携・協力・合意・展示

第9章 企業プロファイル

  • 3M Company
  • Acelity L.P
  • Alliqua BioMedical
  • Bausch Health Companies
  • Bayer
  • BMG Pharma
  • Convatec Group
  • Derma Sciences
  • Friulia S.p.A. Glaxosmithkline
  • Helsinn Healthcare
  • Integra LifeSciences
  • Kannalife
  • Molnlycke Health Care
  • Mylan N.V
  • Rebound Therapeutics
  • Smith & Nephew
  • Stratpharma
図表

List of Tables

  • Table 1 Global Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 2 Global Radiodermatitis Market, by Product, 2019-2032 (USD Million)
  • Table 3 Radiodermatitis Market Assessment, By Geography, 2019-2032 (USD Million)
  • Table 4 North America: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 5 North America: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
  • Table 6 U.S.: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 7 U.S.: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
  • Table 8 Canada: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 9 Canada: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
  • Table 10 Europe: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 11 Europe: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
  • Table 12 UK: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 13 UK: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
  • Table 14 France: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 15 France: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
  • Table 16 Germany: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 17 Germany: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
  • Table 18 Italy: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 19 Italy: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
  • Table 20 Spain: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 21 Spain: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
  • Table 22 Netherlands: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 23 Netherlands: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
  • Table 24 Russia: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 25 Russia: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
  • Table 26 Asia Pacific: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 27 Asia Pacific: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
  • Table 28 China: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 29 China: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
  • Table 30 India: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 31 India: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
  • Table 32 Malaysia: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 33 Malaysia: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
  • Table 34 Japan: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 35 Japan: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
  • Table 36 Indonesia: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 37 Indonesia: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
  • Table 38 South Korea: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 39 South Korea: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
  • Table 40 Middle East & Africa: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 41 Middle East & Africa: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
  • Table 42 Saudi Arabia: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 43 Saudi Arabia: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
  • Table 44 UAE: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 45 UAE: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
  • Table 46 Israel: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 47 Israel: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
  • Table 48 South Africa: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 49 South Africa: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
  • Table 50 Latin America: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 51 Latin America: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
  • Table 52 Mexico: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 53 Mexico: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
  • Table 54 Brazil: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 55 Brazil: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
  • Table 56 Argentina: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 57 Argentina: Radiodermatitis Market, by Product, 2019-2032 (USD Million)

List of Figures

Figure 1 Global Radiodermatitis Market, 2019-2032 (USD Million)

Figure 2 Integrated Ecosystem

Figure 3 Research Methodology: Top-Down & Bottom-Up Approach

Figure 4 Market by Geography

Figure 5 Porter's Five Forces

Figure 6 Market by Distribution Channel

Figure 7 Global Radiodermatitis Market, by Distribution Channel, 2021 & 2030 (USD Million)

Figure 8 Market by Product

Figure 9 Global Radiodermatitis Market, by Product, 2021 & 2030 (USD Million)

Figure 10 Radiodermatitis Market Assessment, By Geography, 2019-2032 (USD Million)

Figure 11 Strategic Analysis - Radiodermatitis Market

目次
Product Code: PM2963

The global radiodermatitis market size is expected to reach USD 649.58 million by 2032, according to a new study by Polaris Market Research. The report "Global Radiodermatitis Market Share, Size, Trends, Industry Analysis Report, By Product (Topical, Oral, and Dressings); By Distribution Channel; By Region; Segment Forecast, 2023-2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Several governing and non-governing bodies are taking constructive steps to promote information regarding accessible radiodermatitis therapy and management items. This is accelerating market expansion along with the increased public and private investments in current research and development (R&D) projects in the life sciences sector. The National Cancer Institute (NCI) monitors how money is spent across diffetent cancer types, cancer-related disorders, and NCI research procedures. The NCI had USD 5.9 Bn in funds available in FY 2018 (including USD 300 Mn in the CURES Act funding), which was up 5%, or USD 284 Mn, from the previous fiscal year. Non-competing grants were provided at 100% of the agreed level under the NCI RPG expense policies.

Furthermore, these groups also disseminate advice on how to treat the condition successfully, which is projected to increase the potential for growth in the extended run. For instance, the BC Cancer Agency of the Provincial Health Services Authority has released data on radiodermatitis treatment. This is anticipated to advance understanding of evaluation and treatment techniques as well as general skincare guidance, enhancing prospective growth. As more clinical studies are carried out to evaluate the efficacy of a range of radiodermatitis therapy items for treatment, it is anticipated that the product pipeline will expand and the market will have lucrative growth potential.

Furthermore, to diversify their product offerings and acquire a competitive advantage, the major firms are concentrating on creating inventive product varieties. In December 2020, It has been announced that Sonoma Pharmaceuticals & Crown Laboratories have reached a deal for the exclusive selliong license & to promote medicine for the OTC dermatological market in the U.S. Crown intends to market Sonoma's Microcyn technology dermal spray and gels that target itch and discomfort under the name Sarna, the #1 Dermatologist approved Anti-Itch Brand, with a distinctive selection of formulations to fast cure itching & skin irritations. Therefore, these collaborations for the launches of dermatologist products are bolstering the growth of radiodermatitis over the forecast period.

Global Radiodermatitis Market Report Highlights

  • The online segment grown at a high CAGR over the study period due to increased patient convenience since it offers goods home delivery. Additionally, patients can receive rebates on radiodermatitis medicines through online pharmacies
  • The retail segment garnered largest of the global revenue share due to the availability of economical product alternatives, neighborhood pharmacies, and the availability of generic versions of medications
  • North America is expected to grow at a high CAGR over the projected period due to the incorporation of radiodermatitis products in healthcare reimbursement policies, an increase in the number of cancer patients
  • The global players in the market include: 3M Company, Acelity L.P., Bayer, Convatec Group, Friulia S.p.A. Glaxosmithkline, Helsinn Healthcare, Kannalife, Molnlycke Health Care, Mylan, Rebound Therapeutics, Smith & Nephew, and Stratpharma.

Polaris Market Research has segmented the global radiodermatitis market report based on distribution channel, product, and region:

Radiodermatitis, Product Outlook (Revenue - USD Million, 2019 - 2032)

  • Topical
    • Corticosteroids
    • Hydrophilic creams
    • Antibiotics
    • Others
  • Oral
    • Dressings
    • Hydrogel & Hydrocolloid dressings
    • No Sting Barrier Film
    • Honey-Impregnated Gauze
    • Silicone Coated Dressings
    • Others

Radiodermatitis, Distribution Channel Outlook (Revenue - USD Million, 2019 - 2032)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online

Radiodermatitis, Regional Outlook (Revenue - USD Million, 2019 - 2032)

  • North America
    • U.S
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Russia
    • Netherlands
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Indonesia
    • Malaysia
  • Latin America
    • Argentina
    • Brazil
    • Mexico
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • Israel
    • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Radiodermatitis Market Insights

  • 4.1. Radiodermatitis Market - Industry Snapshot
  • 4.2. Radiodermatitis Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. High prevalence of cancer
      • 4.2.1.2. Rising adoption of radiotherapy
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High Cost
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Radiodermatitis Industry trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Radiodermatitis Market, by Product

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Radiodermatitis, by Product, 2019-2032 (USD Million)
  • 5.3. Topical
    • 5.3.1. Global Radiodermatitis Market, by Topical, by Region, 2019-2032 (USD Million)
    • 5.3.2. Corticosteroids
      • 5.3.2.1. Global Radiodermatitis Market, by Corticosteroids, by Region, 2019-2032 (USD Million)
    • 5.3.3. Hydrophilic creams
      • 5.3.3.1. Global Radiodermatitis Market, by Hydrophilic creams, by Region, 2019-2032 (USD Million)
    • 5.3.4. Antibiotics
      • 5.3.4.1. Global Radiodermatitis Market, by Antibiotics, by Region, 2019-2032 (USD Million)
    • 5.3.5. Others
      • 5.3.5.1. Global Radiodermatitis Market, by Others, by Region, 2019-2032 (USD Million)
  • 5.4. Oral
    • 5.4.1. Global Radiodermatitis Market, by Oral, by Region, 2019-2032 (USD Million)
  • 5.5. Dressings
    • 5.5.1. Global Radiodermatitis Market, by Dressings, by Region, 2019-2032 (USD Million)
    • 5.5.2. Hydrogel & Hydrocolloid dressings
      • 5.5.2.1. Global Radiodermatitis Market, by Hydrogel & Hydrocolloid dressings, by Region, 2019-2032 (USD Million)
    • 5.5.3. No Sting Barrier Film
      • 5.5.3.1. Global Radiodermatitis Market, by No Sting Barrier Film, by Region, 2019-2032 (USD Million)
    • 5.5.4. Honey-Impregnated Gauze
      • 5.5.4.1. Global Radiodermatitis Market, by Honey-Impregnated Gauze, by Region, 2019-2032 (USD Million)
    • 5.5.5. Silicone Coated Dressings
      • 5.5.5.1. Global Radiodermatitis Market, by Silicone Coated Dressings, by Region, 2019-2032 (USD Million)
    • 5.5.6. Others
      • 5.5.6.1. Global Radiodermatitis Market, by Others, by Region, 2019-2032 (USD Million)

6. Global Radiodermatitis Market, by Distribution Channel

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
  • 6.3. Hospital Pharmacies
    • 6.3.1. Global Radiodermatitis Market, by Hospital Pharmacies, by Region, 2019-2032 (USD Million)
  • 6.4. Retail Pharmacies
    • 6.4.1. Global Radiodermatitis Market, by Retail Pharmacies, by Region, 2019-2032 (USD Million)
  • 6.5. Online
    • 6.5.1. Global Radiodermatitis Market, by Online, by Region, 2019-2032 (USD Million)

7. Global Radiodermatitis Market, by Geography

  • 7.1. Key findings
  • 7.2. Introduction
    • 7.2.1. Radiodermatitis Market Assessment, By Geography, 2019-2032 (USD Million)
  • 7.3. Radiodermatitis Market - North America
    • 7.3.1. North America: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
    • 7.3.2. North America: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
    • 7.3.3. Radiodermatitis Market - U.S.
      • 7.3.3.1. U.S.: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.3.3.2. U.S.: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
    • 7.3.4. Radiodermatitis Market - Canada
      • 7.3.4.1. Canada: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.3.4.2. Canada: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
  • 7.4. Radiodermatitis Market - Europe
    • 7.4.1. Europe: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
    • 7.4.2. Europe: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
    • 7.4.3. Radiodermatitis Market - UK
      • 7.4.3.1. UK: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.4.3.2. UK: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
    • 7.4.4. Radiodermatitis Market - France
      • 7.4.4.1. France: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.4.4.2. France: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
    • 7.4.5. Radiodermatitis Market - Germany
      • 7.4.5.1. Germany: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.4.5.2. Germany: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
    • 7.4.6. Radiodermatitis Market - Italy
      • 7.4.6.1. Italy: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.4.6.2. Italy: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
    • 7.4.7. Radiodermatitis Market - Spain
      • 7.4.7.1. Spain: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.4.7.2. Spain: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
    • 7.4.8. Radiodermatitis Market - Netherlands
      • 7.4.8.1. Netherlands: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.4.8.2. Netherlands: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
    • 7.4.9. Radiodermatitis Market - Russia
      • 7.4.9.1. Russia: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.4.9.2. Russia: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
  • 7.5. Radiodermatitis Market - Asia Pacific
    • 7.5.1. Asia Pacific: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
    • 7.5.2. Asia Pacific: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
    • 7.5.3. Radiodermatitis Market - China
      • 7.5.3.1. China: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.5.3.2. China: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
    • 7.5.4. Radiodermatitis Market - India
      • 7.5.4.1. India: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.5.4.2. India: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
    • 7.5.5. Radiodermatitis Market - Malaysia
      • 7.5.5.1. Malaysia: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.5.5.2. Malaysia: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
    • 7.5.6. Radiodermatitis Market - Japan
      • 7.5.6.1. Japan: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.5.6.2. Japan: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
    • 7.5.7. Radiodermatitis Market - Indonesia
      • 7.5.7.1. Indonesia: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.5.7.2. Indonesia: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
    • 7.5.8. Radiodermatitis Market - South Korea
      • 7.5.8.1. South Korea: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.5.8.2. South Korea: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
  • 7.6. Radiodermatitis Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
    • 7.6.2. Middle East & Africa: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
    • 7.6.3. Radiodermatitis Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.6.3.2. Saudi Arabia: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
    • 7.6.4. Radiodermatitis Market - UAE
      • 7.6.4.1. UAE: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.6.4.2. UAE: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
    • 7.6.5. Radiodermatitis Market - Israel
      • 7.6.5.1. Israel: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.6.5.2. Israel: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
    • 7.6.6. Radiodermatitis Market - South Africa
      • 7.6.6.1. South Africa: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.6.6.2. South Africa: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
  • 7.7. Radiodermatitis Market - Latin America
    • 7.7.1. Latin America: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
    • 7.7.2. Latin America: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
    • 7.7.3. Radiodermatitis Market - Mexico
      • 7.7.3.1. Mexico: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.7.3.2. Mexico: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
    • 7.7.4. Radiodermatitis Market - Brazil
      • 7.7.4.1. Brazil: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.7.4.2. Brazil: Radiodermatitis Market, by Product, 2019-2032 (USD Million)
    • 7.7.5. Radiodermatitis Market - Argentina
      • 7.7.5.1. Argentina: Radiodermatitis Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.7.5.2. Argentina: Radiodermatitis Market, by Product, 2019-2032 (USD Million)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. 3M Company
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Acelity L.P
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Alliqua BioMedical
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. Bausch Health Companies
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Bayer
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. BMG Pharma
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. Convatec Group
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Derma Sciences
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. Friulia S.p.A. Glaxosmithkline
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. Helsinn Healthcare
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development
  • 9.11. Integra LifeSciences
    • 9.11.1. Company Overview
    • 9.11.2. Financial Performance
    • 9.11.3. Product Benchmarking
    • 9.11.4. Recent Development
  • 9.12. Kannalife
    • 9.12.1. Company Overview
    • 9.12.2. Financial Performance
    • 9.12.3. Product Benchmarking
    • 9.12.4. Recent Development
  • 9.13. Molnlycke Health Care
    • 9.13.1. Company Overview
    • 9.13.2. Financial Performance
    • 9.13.3. Product Benchmarking
    • 9.13.4. Recent Development
  • 9.14. Mylan N.V
    • 9.14.1. Company Overview
    • 9.14.2. Financial Performance
    • 9.14.3. Product Benchmarking
    • 9.14.4. Recent Development
  • 9.15. Rebound Therapeutics
    • 9.15.1. Company Overview
    • 9.15.2. Financial Performance
    • 9.15.3. Product Benchmarking
    • 9.15.4. Recent Development
  • 9.16. Smith & Nephew
    • 9.16.1. Company Overview
    • 9.16.2. Financial Performance
    • 9.16.3. Product Benchmarking
    • 9.16.4. Recent Development
  • 9.17. Stratpharma
    • 9.17.1. Company Overview
    • 9.17.2. Financial Performance
    • 9.17.3. Product Benchmarking
    • 9.17.4. Recent Development